Publikationen, an denen er mitarbeitet Jesús María Prieto Valtueña (90)

2017

  1. Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells

    Translational Research, Vol. 188, pp. 80-91.e2

2016

  1. Factors related to increased resting energy expenditure in men with liver cirrhosis

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 2, pp. 139-145

  2. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria

    Journal of Hepatology, Vol. 65, Núm. 4, pp. 776-783

2015

  1. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

2014

  1. Comparación de las sondas M y XL para estimar la rigidez hepática por medio de elastografía de transición

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 4, pp. 233-239

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

  2. Cytokines for the treatment of gastrointestinal cancers: Clinical experience and new perspectives

    Expert Opinion on Investigational Drugs, Vol. 22, Núm. 7, pp. 827-841

  3. Increased liver stiffness values in patients with heart failure

    Acta Gastro-Enterologica Belgica, Vol. 76, Núm. 2, pp. 246-250

  4. Prognostic factors and prevention of radioembolization-induced liver disease

    Hepatology, Vol. 57, Núm. 3, pp. 1078-1087

  5. Safety and liver transduction efficacy of raav5-cohpbgd in nonhuman primates: A potential therapy for acute intermittent porphyria

    Human Gene Therapy, Vol. 24, Núm. 12, pp. 1007-1017

  6. Zolmitriptan: A Novel Portal Hypotensive Agent Which Synergizes with Propranolol in Lowering Portal Pressure

    PLoS ONE, Vol. 8, Núm. 1

2012

  1. Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B

    Hepatology, Vol. 56, Núm. 2, pp. 474-483

  2. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates.

    Journal of translational medicine, Vol. 10, pp. 122

2011

  1. A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma

    Functional and Integrative Genomics, Vol. 11, Núm. 3, pp. 419-429

  2. Adeno-associated virus liver transduction efficiency measured by in vivo [ 18F]FHBG positron emission tomography imaging in rodents and nonhuman primates

    Human Gene Therapy, Vol. 22, Núm. 8, pp. 999-1009

  3. Characterization of woodchuck apolipoprotein A-I: A new tool for drug delivery and identification of altered isoforms in the woodchuck chronic hepatitis model

    Journal of Medical Virology, Vol. 83, Núm. 7, pp. 1221-1229

  4. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection

    Journal of Hepatology, Vol. 54, Núm. 3, pp. 422-431

  5. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages

    Annals of Surgical Oncology, Vol. 18, Núm. 7, pp. 1964-1971

  6. Transarterial therapies for hepatocellular carcinoma

    Expert Opinion on Pharmacotherapy, Vol. 12, Núm. 7, pp. 1057-1073

  7. Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of Interleukin-12

    Journal of Virology